Equipoise is a steroid ester possessing marked anabolic properties and a minimal amount of androgenic activity.

Anabolic and androgenic agents have come to be used widely in the treatment of certain pathophysiological or catabolic processes in man and animals. In many instances it is desirable to maintain a constant level of effect over a long period of time. Equipoise is a long-acting injectable agent which has a rapid onset of action; this is advantageous and is preferred over frequent oral dosing or even repeated injections.

Actions

Anabolic agents are related to the sex hormones, but each varies in its anabolic and androgenic effect. Compounds such as methyltestosterone have anabolic activity, but with prolonged use, animals develop marked androgenic activity which makes these compounds unsuitable for prolonged therapy.

Pharmacological studies conducted in laboratory animals to evaluate the pharmacological activity characterized Equipoise as having distinct anabolic properties together with a certain degree of androgenic activity. It does not have marked antigonadotropic properties nor does it produce any clear-cut effects on the endometrium, conditions that are commonly observed when similar substances are used.

In clinical trials, at the recommended dosage, Equipoise had a marked anabolic effect in debilitated horses; appetite improved, vigor increased and improvement was noted in musculature and haircoat. This would be expected with an anabolic agent such as Equipoise, particularly where there had been marked tissue breakdown associated with disease, prolonged anorexia or overwork.

Equipoise Indications

Equipoise (Boldenone Undecylenate Injection) is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and overexertion.

Equipoise improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized.

Equipoise should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases and traumatic injuries.

Equipoise Dosage And Administration

The dosage for horses is 0.5 mg per pound of body weight intramuscularly. Treatment may be repeated at three week intervals.

The condition should be assessed by the veterinarian to determine the duration of treatment; however, most horses will respond with one or two treatments.

Adverse Reactions

With Equipoise (Boldenone Undecylenate Injection), androgenic (over aggressiveness) effects may be noted in a few animals. If these effects occur, they may persist for up to 6 to 8 weeks. No additional injections of boldenone undecylenate should be administered.

Warnings

For horses only. Do not use in horses intended for human consumption. In the absence of data on the effect of boldenone undecylenate on stallions, on pregnant mares and the teratogenicity on the offspring, this drug should not be used in these animals.

How Supplied

Equipoise is supplied for veterinary use in a vial providing 50 mg boldenone undecylenate per mL.

Every effort has been made to ensure the accuracy of the Equipoise information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.